Apps

Novo Nordisk Halts Two Ziltivekimab Heart Trials — 5dNovo Nordisk has halted two more ziltivekimab trials in heart failure after a data monitor found limited likelihood of success, adding to the earlier ZEUS setback and leaving only the post‑myocardial infarction ARTEMIS study as the remaining program. A separate post‑MI study is continuing with results expected in early 2027, underscoring ongoing challenges for inflammation‑targeting cardiovascular therapies.

Rachel Meyers Kind of telling that they're still holding onto that one post-MI study though. Guess we'll see if there's a specific subgroup where this actually works.

Novo says Wegovy trial moved 40% of young children out of obesity — 5dIn Novo Nordisk's STEP Young phase 3 trial, once-weekly semaglutide plus lifestyle changes reduced BMI and 40.4% of children aged 6-11 with obesity no longer met obesity criteria after 68 weeks, versus 0% on placebo. Safety remained consistent with prior semaglutide studies, adding to the growing body of pediatric obesity treatment data.

Chris Dalton Glad there's finally something beyond diet and exercise lectures for kids who genuinely struggle, this could change a lot of families' lives.

Novo Nordisk launches Wegovy pill in Germany as Eli Lilly readies rival — Sep 1, 2026Novo Nordisk is rolling out Wegovy as an oral weight‑loss pill in Germany, the EU’s first market to receive the formulation after EU approval, with prices expected around €170–€280 and strong competition from Eli Lilly’s Foundayo on the horizon. The launch leverages Wegovy’s dominant position in the oral obesity market, while analysts weigh the impact of the tablet on growth, pricing, and payer access across Europe.

Tom Gallagher Curious how many insurers in Germany will actually cover this at launch, oral obesity meds still feel like they're priced for a niche market.

Video — YouTubeJon on Trump's Meme Assault on Canada & the Alternate Reality He's Constructed | The Daily ShowThe Daily Show · 8.6M views · Sep 9, 2026

21:06

Analysts see recovery potential in Intuitive Surgical and Novo Nordisk amid growth worries — Sep 4, 2026Stock picks across a mix of growth and large-cap names show a balance of long-term upside and near-term headwinds: Intuitive Surgical and Novo Nordisk are presented as attractive long-term buys despite recent challenges, while TXN and ODFL face slowing growth and margin pressure, warranting caution on valuation. Additional lists flag mixed signals for Teradata and RUM Group, Allegro MicroSystems and First Watch as high- or mid-duration risks, Twilio and ADM as examples of growth or margin struggles in large-cap names, underscoring the broader theme of weighing quality against price in today’s market.

Jared Kim Intuitive Surgical has been the steady long term compounder for years, short term wobbles don't scare me off that one.

China's Novo Nordisk Oral Wegovy Filing AcceptedBusiness — Aug 27, 2026Novo Nordisk trades near its average price target as China regulators accept the oral Wegovy application, underscoring a regulatory catalyst amid strong GLP-1 growth potential. The China market is heating up with Eli Lilly and others racing to offer pill-based options, and analysts project GLP-1 sales in China to surge to around 30 billion yuan in the next five to seven years, driving competition and market leadership shifts.

Novo Resources outlines near-term drilling, investment plans across gold, copper portfolio — Aug 24, 2026Novo Resources is pursuing a discovery-led gold and copper exploration strategy across its Australian portfolio, including Belltopper and Toolunga, supported by cash reserves and a $36 million San Cristobal investment to fund drilling and potential acquisitions. It has updated its corporate presentation to outline strategic priorities, exploration progress, and near-term catalysts, with NI 43-101/JORC-compliant disclosures across ASX, TSX, and OTC listings to inform investors.

Novo Nordisk Tests Lower Wegovy Doses — Aug 19, 2026Novo Nordisk is conducting a late-stage study to identify the lowest effective dose of Wegovy, testing two low doses against placebo in 450 participants as it seeks to preserve its share in a obesity drug market projected to exceed $100 billion annually by 2030. The trial, which began on August 12 and runs through 2028, follows competitive pressure from Eli Lilly and comes after Wegovy's recent sales performance, with dose strengths undisclosed.

J&J Wins FDA De Novo OTTAVA System — Jul 22, 2026Johnson & Johnson has received FDA De Novo clearance for its Ottava robotic surgical system, marking its entry into the U.S. market as a table-integrated, space-saving alternative aimed at general soft-tissue procedures. The company plans a selective U.S. rollout and ongoing global expansion, supported by an inguinal hernia trial and continued development of additional indications and regulatory approvals amid competition from Intuitive Surgical's established da Vinci platform.

Pharma Exec Passes Out In Oval Office As Dr. Oz Rushes To His Aid — Nov 6, 2025Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz rushed to the aid of Novo Nordisk executive Gordon Findlay as he passed out inside the Oval Office on Thursday. President Donald Trump, Oz, Health…

China obesity rate expected above 65% by 2030 — Aug 24, 2026China’s National Health Commission suggests obesity could exceed 65% of the population by 2030, triggering a push by major drugmakers to promote GLP-1 weight-loss injections through indirect public advertising in places like metro stations and stadiums due to bans on direct prescription-drug ads. Companies including Novo Nordisk, Lilly, Pfizer, and Innovent Biologics are vying for market share, with Lilly leading online sales on Alibaba/JD.com and campaigns emphasizing obesity risks and related conditions such as sleep apnea without naming products.

Video — YouTubeThe Perfect Team Nobody Expected❤️Warm Land · 9.2M views · Sep 9, 2026

0:25

Trump Announces $250 Weight Loss Drugs In Latest ‘TrumpRx’ Deal — Nov 6, 2025President Donald Trump unveiled steep discounts on GLP-1 weight loss drugs in deals with pharmaceutical giants Eli Lilly and Novo Nordisk in a Thursday Oval Office announcement. The obesity drugs Zepbound, marketed by…

Nestlé Uses AI to Target GLP-1 UsersHealth — Aug 14, 2026The rapid rise of GLP-1 weight‑loss drugs is reshaping the market as Nestlé leverages AI to turn potential threats into opportunities by developing nutrition products and addressing drug side effects, while major pharma players like Lilly and Novo Nordisk navigate revenue trajectories and competitive disputes. Across the industry, executives see GLP-1 therapies expanding beyond weight loss into broader health benefits, with AstraZeneca highlighting broader applications and regulators flagging safety and counterfeit risks as demand climbs.

Boa Constrictor Wins Met Opera Snake Auditions — Sep 5, 2026Snakes auditioned at the Metropolitan Opera for Così fan tutte; a boa constrictor named Princess won the role with understudy Nala, chosen by performer Zoe Ziegfeld who handles the snake on stage. The production is staged as a 1950s Coney Island carnival with animal talent expert Nancy Novograd supplying the snakes for the auditions.

Rachel Meyers Zoe Ziegfeld has got one of the more unusual job descriptions on Broadway, handling a boa constrictor for a Coney Island carnival scene.

US plans outdoor GMO screwworm tests in PanamaScience — Jul 23, 2026Scientists at a U.S.-funded Panama facility are beginning outdoor tests of genetically modified screwworm flies to strengthen a longstanding eradication effort as the flesh-eating parasite reappears in Texas; the program centers on NovoFly, a male-only sterility approach, with production considerations expanding to a Texas facility to meet looming needs. Experts say widespread releases and international cooperation will likely extend over more than a year, but supporters argue the technology could be the most significant advance in livestock pest control since the original sterile-insect program that eliminated screwworms in the U.S. decades ago.

Nvidia H200 shipments enter China, ByteDance Tencent receive — Aug 19, 2026Nvidia’s H200 AI chips are arriving in mainland China in small batches, with ByteDance and Tencent each receiving about 10,000 units under a regime that allows up to 100,000 per Chinese buyer. Beijing is balancing demand for high-performance AI computing with a push to bolster domestic semiconductor capabilities, permitting shipments to Hong Kong and encouraging resumption of orders through partners like Lenovo while Nvidia works to clear inventory.

Developing storylines

Novo Nordisk's mixed drug trial results across therapies